Pfizer (PFE 0.77%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Bispecific anti-PD1/VEGF remains one of the hottest topics in the oncology field. Click here for a detailed analysis.

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

Pfizer’s top cancer drugs are small molecules ... Furthermore, the big pharma has committed to a $100 million equity investment in 3SBio. The 3SBio drug, SSGJ-707, treats cancer by blocking ...

CellCentric has secured a Series C raise of $120million to advance its drug inobrodib, a first-in-class oral cancer drug to ...

In exchange, 3SBio will receive $1.25bn upfront from Pfizer and will be eligible for certain development, regulatory and ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Government signs deal to see huge investment in mRNA vaccine manufacturing which could help tackle the next pandemic and ...

CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

With that in mind, let's consider two high-yield dividend stocks worth investing in: Pfizer (NYSE: PFE) and Medical ...

The Global Nanomedicine Market is expected to witness a growth rate of 10-12% in the next five years. Ongoing research and ...

HER2-negative metastatic breast cancer patients whose tumours expressed ESR1 mutations, but the drug couldn't achieve the same result for the full cohort. The finding dents Pfizer hopes that ...